"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. Bronchopulmonary Dysplasia- Overview
3. Executive Summary
4. Bronchopulmonary Dysplasia: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Bronchopulmonary Dysplasia: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. Transplantation of hUC-MSCs – Children's Hospital of Chongqing Medical University.
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. Furosemide Cohort 1 – University of North Carolina
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. PNEUMOSTEM – MEDIPOST Co., Ltd.
5.1.3.1. Company Overview
5.1.3.2. Product Description
5.1.3.3. R&D Status & Development Activities
5.1.3.4. Mechanism of Action
5.1.3.5. Molecule Type
5.1.3.6. Stage of Development
5.1.3.7. Indications
5.1.3.8. Route of Administration
5.1.3.9. Funding
5.1.4. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. Bronchopulmonary Dysplasia: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. Bronchopulmonary Dysplasia: Additional Key Insights
7.1. Epidemiology Overview: Bronchopulmonary Dysplasia
7.2. Current Market Scenario: Bronchopulmonary Dysplasia Therapeutics
8. Bronchopulmonary Dysplasia: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.